Innovent Biologics Reports the P-II Trial Data of Picankibart (IBI112) in Chinese Patients with Ulcerative Colitis
Shots:
- Innovent reported results from the P-II study assessing safety & efficacy of picankibart vs PBO in Chinese patients (n=150) with mod. to sev. active UC, receiving 200mg/600mg at wks.0, 4 & 8 during induction & 200mg Q4/8W during maintenance
- Trial achieved the 1 & 2EPs, showing clinical remission in 20% & 14% vs 2% and clinical response in 54% & 68% vs 22%. Patients also experienced symptomatic remission, endoscopic remission, or histologic-endoscopic mucosal remission with both the doses
- The ongoing maintenance period shows increasing rates of clinical remission, response, symptomatic remission & endoscopic or mucosal remission vs induction. Data analysis will continue & will be published in academic congresses or clinical journals
Ref: Innovent Biologics | Image: Innovent Biologics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
